Intellicheck To Announce Second Quarter 2025 Financial Results on August 12, 2025
The Company will hold an earnings conference call on August 12 at 4:30 p.m. ET/1:30 p.m. PT to discuss operating results. To listen to the earnings conference call, please dial 877-407-8037. For callers outside the U.S., please dial 201-689-8037.
A replay of the conference call will be available shortly after completion of the live event. To listen to the replay, please dial 877-660-6853 and use conference identification number 13754628. For callers outside the U.S., please dial 201-612-7415 and use conference identification number 13754628. The replay will be available beginning approximately three hours after the completion of the live event and will remain available until August 19, 2025.
About Intellicheck
Intellicheck, the industry leader in identity verification management, prevents the unauthorized use of IDs to stop identity-based fraud. Intellicheck is the only SaaS-based validation and proofing service that uses a unique and proprietary analysis of DMV-issued IDs to create trusted, real-time customer identity verification experiences across a wide variety of sectors, both in-person and digitally. Each year, we validate around 100 million identities across North America, providing a seamless, invisible ID verification with 100% decisioning in under a second. For more information on Intellicheck, visit us on the web and follow us on LinkedIn, X, Facebook, and YouTube.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Ryvyl Second Quarter 2025 Earnings: US$0.36 loss per share (vs US$1.88 loss in 2Q 2024)
Ryvyl (NASDAQ:RVYL) Second Quarter 2025 Results Key Financial Results Revenue: US$2.78m (down 77% from 2Q 2024). Net loss: US$3.84m (loss narrowed by 68% from 2Q 2024). US$0.36 loss per share (improved from US$1.88 loss in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Ryvyl shares are down 5.8% from a week ago. Risk Analysis Before we wrap up, we've discovered 5 warning signs for Ryvyl (4 can't be ignored!) that you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) is definitely on the radar of institutional investors who own 38% of the company
Explore Drugs Made In America Acquisition's Fair Values from the Community and select yours Key Insights Significantly high institutional ownership implies Drugs Made In America Acquisition's stock price is sensitive to their trading actions 51% of the business is held by the top 9 shareholders Ownership research, combined with past performance data can help provide a good understanding of opportunities in a stock We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Every investor in Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 38% to be precise, is institutions. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. Therefore, a good portion of institutional money invested in the company is usually a huge vote of confidence on its future. Let's delve deeper into each type of owner of Drugs Made In America Acquisition, beginning with the chart below. Check out our latest analysis for Drugs Made In America Acquisition What Does The Institutional Ownership Tell Us About Drugs Made In America Acquisition? Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. As you can see, institutional investors have a fair amount of stake in Drugs Made In America Acquisition. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Drugs Made In America Acquisition's historic earnings and revenue below, but keep in mind there's always more to the story. It would appear that 16% of Drugs Made In America Acquisition shares are controlled by hedge funds. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. The company's largest shareholder is Drugs Made In America Acquisition LLC, with ownership of 12%. Karpus Management Inc. is the second largest shareholder owning 6.9% of common stock, and First Trust Capital Management L.P. holds about 6.2% of the company stock. We also observed that the top 9 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent. While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. We're not picking up on any analyst coverage of the stock at the moment, so the company is unlikely to be widely held. Insider Ownership Of Drugs Made In America Acquisition The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances. We can see that insiders own shares in Drugs Made In America Acquisition Corp.. As individuals, the insiders collectively own US$4.1m worth of the US$345m company. It is good to see some investment by insiders, but it might be worth checking if those insiders have been buying. General Public Ownership The general public-- including retail investors -- own 32% stake in the company, and hence can't easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run. Private Company Ownership We can see that Private Companies own 12%, of the shares on issue. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company. Next Steps: I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Be aware that Drugs Made In America Acquisition is showing 4 warning signs in our investment analysis , and 2 of those make us uncomfortable... If you would prefer check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, backed by strong financial data. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
32 minutes ago
- Yahoo
Is This Beaten-Down Stock a Buy on the Dip?
Key Points Vertex faced some setbacks with two pipeline programs in acute and neuropathic pain. However, the company still has a path forward for both of those medicines. It has several other pipeline candidates and a lineup that generates consistent results. 10 stocks we like better than Vertex Pharmaceuticals › Even well-established drugmakers can lose significant market value overnight following a setback. That's what recently happened to Vertex Pharmaceuticals (NASDAQ: VRTX). The company's shares fell by more than 10% after it announced not-so-great regulatory and clinical developments. Vertex's stock is down 4% year to date following this decline. Should you consider investing in the company's shares while they're down? Let's find out. Vertex's pain franchise faces another obstacle Vertex Pharmaceuticals is targeting the pain treatment market as part of its efforts to diversify its lineup of medicines. In January, the company earned approval for Journavx, the first oral non-opioid pain signal inhibitor, for the treatment of moderate to severe acute pain. However, the drugmaker has encountered some headwinds in this niche. Journavx did not perform as well as expected in a phase 2 study in patients with painful lumbosacral radiculopathy. Vertex's shares plummeted in December following that data readout. And although the company initially stated it would pursue this indication for Journavx despite the unimpressive mid-stage data, it recently announced it was abandoning those plans based on feedback from regulators. That was one reason Vertex's shares fell hard. Then there's VX-993, an investigational therapy for acute pain that just failed phase 2 studies. Vertex will not pursue VX-993 as a monotherapy in this indication. This is the second development responsible for the company's shares recently plummeting. Why the stock is still attractive Despite these clinical setbacks, Vertex's shares remain a worthwhile investment for long-term investors. Let's consider four reasons why. First, the company's financial results remain strong. In the second quarter, revenue increased by 12% year over year to $2.96 billion. Vertex's cystic fibrosis (CF) business continues to perform well, and the recent addition of its next-gen CF medicine Alyftrek should help. Vertex is the only company that markets drugs for the underlying causes of CF, but many patients in the geographies it targets are still not benefiting from its therapies. So the company still has some headway in its core franchise. Second, Vertex has successfully diversified its lineup in recent years. In addition to Journavx, the biotech earned approval for Casgevy, a gene-editing therapy for two rare blood disorders, in 2023. While these products aren't contributing much to financial results yet, they eventually will. Vertex noted that Journavx's launch is going well. It has secured third-party coverage for approximately 150 million Americans, which suggests there's a reasonable demand for the medicine. Third, Vertex should still make some headway in the market for pain treatments. It's enrolling patients for phase 3 studies of Journavx in diabetic peripheral neuropathy, while VX-993 will also be tested in mid-stage clinical trials in this indication. Fourth, the company has several other exciting pipeline candidates. One of them is zimislecel, an investigational therapy for type 1 diabetes (T1D) that's posting strong results in clinical trials and could become an approved functional cure for T1D. It helps restore patients' ability to produce their own insulin, something that is normally not possible with this chronic health condition. Vertex plans on submitting regulatory applications for it next year. The late-stage pipeline also features inaxaplin, a potential treatment for APOL-1-mediated kidney disease, a condition for which there are no approved therapies that target the underlying causes. Even well-established biotech companies like Vertex Pharmaceuticals face clinical setbacks that sink their stock prices. But in this case, given Vertex's strong lineup and pipeline and its consistent financial results, this seems like an excellent opportunity to purchase its shares on the dip. Should you invest $1,000 in Vertex Pharmaceuticals right now? Before you buy stock in Vertex Pharmaceuticals, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Vertex Pharmaceuticals wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $663,630!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,695!* Now, it's worth noting Stock Advisor's total average return is 1,071% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Is This Beaten-Down Stock a Buy on the Dip? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
